Orforglipron
InvestigationalAlso known as: LY3502970, Eli Lilly oral GLP-1
GLP-1 AgonistLast reviewed: April 28, 2026
A non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and tirzepatide which are peptides requiring injection, orforglipron is a fully oral pill taken once daily with no fasting requirement. Phase 3 trials are underway, potentially making it the first truly convenient oral GLP-1 option.
Mechanism of Action
Activates GLP-1 receptors through a non-peptide chemical scaffold, producing the same downstream effects as injectable GLP-1 agonists — appetite suppression, insulin secretion, and slowed gastric emptying. The oral bioavailability is achieved through its small-molecule structure, unlike oral semaglutide (Rybelsus) which requires strict fasting protocols.
Common Uses
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic health improvement
Known Risks
- GI side effects (nausea, diarrhea, vomiting) — similar to injectable GLP-1s
- Still in Phase 3 trials — full safety profile not established
- Long-term cardiovascular outcomes data not yet available
- Not yet approved for any indication
Regulatory Status
Currently in Phase 3 clinical trials for obesity and type 2 diabetes. Phase 2 results showed ~14.7% weight loss at 36 weeks — comparable to injectable semaglutide. If approved, would be the first non-peptide oral GLP-1 agonist, removing the injection barrier for many patients. Potential approval 2026-2027.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral tablet (investigational)
Typical Dose
12–45 mg (dose range studied in trials)
Frequency
Once daily
Cycle Length
Ongoing — not commercially available
Not yet approved or available outside clinical trials. Unlike Rybelsus (oral semaglutide), does not require fasting before administration — a significant practical advantage if approved.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.